By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kolltan Pharmaceuticals Inc. 

300 George Street
Suite 530
New Haven  Connecticut  06511  U.S.A.
Phone: 203-773-3000 Fax: 203-773-1300


SEARCH JOBS

Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.


Key Statistics


Email: info@kolltan.com
Ownership: Private

Web Site: Kolltan Pharma
Employees:
Symbol: 
 









Company News
Celldex (CLDX) Completes Acquisition Of Kolltan Pharma 11/30/2016 8:14:46 AM
Fosun Pharma Acquires Cancer Drug Candidate From US-based Kolltan Pharma 11/4/2016 10:58:53 AM
Celldex (CLDX) Takes Out Kolltan Pharma in $235 Million Deal 11/2/2016 5:42:54 AM
ASCO2016: Kolltan Pharmaceuticals Inc. Presents Clinical Data For KTN3379 In An Oral Presentation At The 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 6/6/2016 7:56:32 AM
Kolltan Pharmaceuticals Inc. To Report KTN3379 Clinical Data In An Oral Presentation At The Upcoming 2016 ASCO Annual Meeting 5/19/2016 11:49:28 AM
Kolltan Pharmaceuticals Inc. To Present Preclinical Data At The 2016 AACR Annual Meeting 3/28/2016 6:48:49 AM
Kolltan Pharmaceuticals Inc. Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones 1/8/2016 8:10:19 AM
Kolltan Pharmaceuticals Inc. To Present At The Stifel 2015 Healthcare Conference 11/13/2015 11:27:51 AM
Kolltan Pharmaceuticals Inc. Presents KTN3379 Preclinical Data At The AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics 11/6/2015 11:46:37 AM
Kolltan Pharmaceuticals Inc. Presents Anti-KIT Antibody Preclinical Data At The 30th Annual Society For Immunotherapy Of Cancer (SITC) Conference 11/6/2015 11:44:59 AM
1234
//-->